{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:43:19Z","timestamp":1792806199857,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113437","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:35:26Z","timestamp":1783985726000},"page":"113437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants"],"prefix":"10.1016","volume":"239","author":[{"given":"Xiaohua","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.diabres.2026.113437_b0005","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/db23-0972","article-title":"GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss","volume":"73","author":"Della Pepa","year":"2024","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.diabres.2026.113437_b0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2026.113437_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnut.2015.00023","article-title":"The L-cell in nutritional sensing and the regulation of appetite","volume":"2","author":"Spreckley","year":"2015","journal-title":"Front Nutr"},{"issue":"4","key":"10.1016\/j.diabres.2026.113437_b0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.diabres.2026.113437_b0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-WEEKLY semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113437_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113437_b0035","article-title":"GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes","volume":"2018","author":"Del Olmo-Garcia","year":"2018","journal-title":"J Diab Res"},{"issue":"6","key":"10.1016\/j.diabres.2026.113437_b0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diabres.2026.113437_b0045","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2337\/dc16-1974","article-title":"Type 2 diabetes in the real world: the elusive nature of glycemic control","volume":"40","author":"Edelman","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113437_b0050","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2147\/PPA.S106821","article-title":"Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors","volume":"10","author":"Polonsky","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.diabres.2026.113437_b0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/PPA.S14477","article-title":"Multinational Internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication","volume":"4","author":"Dibonaventura","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.diabres.2026.113437_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2026.113437_b0065","unstructured":"US Food and Drug Administration. Rybelsus\u00ae (semaglutide) tablets: prescribing information. 2023. https:\/\/ www. acces sdata. fda. gov\/ spl\/ data\/ fa74b bc6- 5386- 425e- 8d4a- 61517 95ba5 7b\/fa74b bc6- 5386- 425e- 8d4a- 61517 95ba5 7b. xml."},{"issue":"467","key":"10.1016\/j.diabres.2026.113437_b0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.diabres.2026.113437_b0075","article-title":"The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects","author":"Liu","year":"2025","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabres.2026.113437_b0080","article-title":"Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: a randomized, double-blind, phase 1b\/2a trial","author":"Liu","year":"2026","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113437_b0085","article-title":"GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: a randomized, placebo-controlled, phase 1b\/2a trial","volume":"7","author":"Ji","year":"2026","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113437_b0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-026-02586-8","article-title":"Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"11","author":"Ji","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.diabres.2026.113437_b0095","article-title":"Weekly and biweekly treatment with bofanglutide versus semaglutide in Chinese patients with type 2 diabetes: a phase 2b randomized clinical trial","author":"Liu","year":"2026","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113437_b0100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.diabres.2026.113437_b0105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s13300-021-01078-y","article-title":"Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation","volume":"12","author":"B\u00e6kdal","year":"2021","journal-title":"Diab Therapy: Res Treat Edu Diab Related Disorders"},{"issue":"15","key":"10.1016\/j.diabres.2026.113437_b0110","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"J Am Med Assoc"},{"issue":"8","key":"10.1016\/j.diabres.2026.113437_b0115","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1111\/dom.15624","article-title":"A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects","volume":"26","author":"Xie","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113437_b0120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40262-023-01223-9","article-title":"Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: a randomised trial in healthy subjects","volume":"62","author":"van Hout","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diabres.2026.113437_b0125","doi-asserted-by":"crossref","unstructured":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug discovery today Technologies 2012; 9(2): e71-e174.","DOI":"10.1016\/j.ddtec.2012.06.004"},{"key":"10.1016\/j.diabres.2026.113437_b0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7326\/0003-4819-98-3-418_2","article-title":"Drug dose and pharmacokinetics","volume":"98","author":"Bottemiller","year":"1983","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113437_b0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2026.113437_b0140","doi-asserted-by":"crossref","DOI":"10.2337\/db25-737-P","article-title":"737-P: HDM1002 in Chinese adults with overweight or obesity\u2014a randomized, placebo-controlled, four-week, phase 1b study","volume":"74","author":"Xu","year":"2025","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.diabres.2026.113437_b0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726003578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:16:28Z","timestamp":1792804588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726003578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0168822726003578"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113437","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113437"}}